Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin
详细信息 查看全文
- 作者：Chantelle Brownea ; chantelle.browne@evidera.com" class="auth_mail" title="E-mail the corresponding author ; Noemi Muszbeka ; Ruth Chapmana ; Kevin Marsha ; Ian M. Gouldb ; R. Andrew Seatonc ; Mike Allend
- 关键词：Infective endocarditis ; Cost effectiveness ; Daptomycin ; Vancomycin
- 刊名：International Journal of Antimicrobial Agents
- 出版年：2016
- 出版时间：May 2016
- 年：2016
- 卷：47
- 期：5
- 页码：357-361
- 全文大小：519 K
文摘
- class="listitem" id="list_lis0005">
- class="label">•
Vancomycin resistance has caused greater interest in the use of daptomycin.
- class="label">•
Daptomycin lowers clinical failure rates compared with vancomycin in patients with Staphylococcus aureus-induced bacteraemia-infective endocarditis.
- class="label">•
Daptomycin can also lower costs as it can reduce the length of stay.
- class="label">•
This is more likely with outpatient parenteral antibiotic therapy.